Clinical Trial Update: Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of vorinostat combined with decitabine in adults with advanced solid tumors or relapsed/refractory hematologic cancers, including various AML, ALL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Myelogenous Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Dacogen (decitabine)
• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Status: COMPLETED